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Abstract
Naxos disease is a genetic cardiocutaneous syndrome manifesting with a  
cardiomyopathy that belongs in the arrhythmogenic right ventricular cardiomy-
opathy (ARVC) spectrum and follows an autosomal recessive pattern. It manifests 
with wooly hair, keratosis of the extremities and right ventricular dysfunction. It 
is accompanied by risk of arrhythmias as well as sudden cardiac death (SCD), even 
at a young age. Furthermore, the disease often progresses to right ventricular heart 
failure, but can also affect the left ventricle. Patient management follows current 
guidelines on ARVC and principles for heart failure management. Bioengineering 
and research about pluripotent stem cells seem to have potential to improve future 
management of the disease. This chapter covers current knowledge on Naxos  
disease regarding clinical features, epidemiology, pathogenesis, guidelines on 
patient management and provides insights in research frontlines.
Keywords: arrhythmias, cardiomyopathy, genetics, heart failure, Naxos disease, 
sudden cardiac death
1. Introduction
Naxos disease is an arrhythmogenic cardiomyopathy, considered to represent a 
form of ARVC [1]. It is of genetic origin and two main proteins have been associ-
ated with the disease. The clinical manifestations include wooly hair, keratosis 
of the extremities, and right ventricular dysfunction. Albeit rare, the disease can 
cause advanced heart failure and life-threatening arrhythmias, even in the young 
[2]. Data on Naxos disease are limited, and current patient management follows 
the guidelines for heart failure and ARVC. In recent years, research has focused 
on the field of bioengineering, illuminating some of the aspects of the disease 
and cultivating future perspectives regarding its management. In this chapter 
we present current knowledge regarding the clinical presentation, epidemiology, 
genetic substrate, pathophysiology, current guidelines for patient management, 
and future paths for Naxos disease.
2. Clinical presentation of Naxos disease
Naxos disease manifests with a typical phenotype including both cardiac and 
extracardiac characteristics. The extracardiac manifestation of the disease involves 
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tight, wooly and rough hair, commonly present from birth [3]. In addition, Naxos 
patients exhibit diffuse palmoplantar non-epidermolytic keratosis, with clear bor-
ders, manifesting as soon as the child starts using hands and feet [3, 4]. Small arms 
and hands, short fingers, curved nails and hypo/oligodontia have also been reported 
in some cases [5, 6]. Notably, heterozygous carriers do not display certain aspects of 
the disease, such as palmoplantar keratoderma but wooly hair may manifest [7].
Regarding the cardiac characteristics, the disease resembles the ARVC pheno-
type. Echocardiography frequently portrays right ventricular dysfunction. In more 
detail, prominent dilation is often present along with hypokinesia and aneurysms 
that affect mainly the outflow tract, apex, and inferior wall of the right ventricle 
[3, 7]. In a quarter of the cases, the left ventricle is also affected, exhibiting the 
same characteristics as seen in dilated cardiomyopathy [4]. The term ‘triangle 
of dysplasia’ has been suggested in Naxos disease, which refers to aneurysms of 
the outflow tract, apex, and posterior wall of the right ventricle [8]. The disease 
prognosis is generally adverse [8]. The annual cardiac mortality reaches 3.0% [7].
While the extra-cardiac manifestations are prominent from a young age, symp-
toms suggestive of cardiac involvement usually occur in adolescence and in young 
adulthood. Heart failure and life-threatening ventricular arrhythmias may occur 
in adolescence [4]. Palpitations, syncope, and atrial arrhythmias are frequently 
encountered [5]. Arrhythmic events involve a wide range of patterns, from numer-
ous premature ventricular complexes to sustained ventricular tachycardia (VT) 
and are present in half of the patients [7]. Events of VT, most commonly of a left 
bundle branch block (LBBB) pattern suggestive of right ventricular origin [9], have 
been documented in Naxos disease, even being drug-refractory in some cases [5]. 
Symptomatic patients tend to exhibit inducible VT in electrophysiology studies [3].
Symptoms suggestive of right ventricular dysfunction occur in advanced heart 
failure [8], while heart failure, either right- or bi-ventricular affects half of the 
patients after 10-year follow-up after diagnosis [7]. When severe hypokinesia 
is present in the context of progression of heart failure, intra-cardiac thrombi 
may occur [10]. Heterozygous carriers do not display ventricular arrhythmias 
or late potentials on signal-averaged electrocardiography (ECG), but atypical 
ECG or echocardiographic discrepancies may occur [7]. Similarly, they did not 
display symptoms or echocardiographic abnormalities in follow-up, in a paper by 
Protonotarios et al. [7].
3. Epidemiology and genetic substrate
Naxos disease has been identified as a form of ARVC inherited in an autosomal 
recessive pattern by the World Health Organization since 1995 [11]. However, 
the disease was first described in 1986, when Protonotarios and associates first 
documented the disease manifestations and clinical course [5]. The name “Naxos” 
originates from this original description of the disease; nine patients, aged 7 to 
41 years, from four families of Naxos island in Greece, were presented. All these 
patients had wooly hair and palmoplantar keratosis as well as a range of arrhythmic 
events, including VT. Interestingly, all patients had echocardiographic signs of 
right ventricular (RV) dysfunction, while in some the left ventricle (LV) was also 
affected [5]. Since then, more patients have been found not only in Greece, but in 
Israel, Saudi Arabia, Italy, and Turkey [12]. Sporadic cases of the disease have also 
been identified in Bangladesh and in Canada [13, 14]. The prevalence of the disease 
in the Greek islands has been calculated to 1:1000 [3]. Officially, the disease was 
first named “Naxos disease” in a 1994 abstract [15]. Of interest, since ARVC and 
its clinical spectrum has been found to manifest with biventricular or mainly LV 
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dysfunction, the term arrhythmogenic cardiomyopathy (ACM) has been proposed 
as more accurate [1]. Prevalence of heterozygous carriers is up to 5% in the Naxos 
population [8].
The proposed recessive hereditary pattern and the resemblance of the disease to 
ARVC [5, 16], was confirmed in 1998, when its locus was identified in chromosome 
17 in position q21 [17], and in 2000 when plakoglobin was identified as the mutated 
protein attributed to the disease [18]. Since then, research has concluded that the 
causative mutation (Pk2157del2TG) is in the gene truncating the C-terminal of the 
protein plakoglobin [3, 12]. In addition, another mutation, the homozygous 2-bp 
deletion (c.2157delTG) (also in the protein plakoglobin) has been associated with 
the disease [18]. Furthermore, mutations of the protein desmoplakin have been 
identified to cause cardiocutaneous ARVC [19, 20]. Early data suggested that Naxos 
disease was a more severe form of ARVC [12], while a more recent comparison 
between the two entities indicates a similar cardiac phenotype, easily identified 
through non-invasive screening [2, 21]. In 2017, a novel homozygous mutation 
was discovered to cause Naxos disease, in unrelated patients of French-Canadian 
families. This is a mutation of the exon 5 of the JUP gene (p.Glu301 Gly) [14]. 
Two mutations of the desmoplakin gene have been implicated; Dsp7901del1G and 
DspG2375R [19, 20]. All aforementioned mutations follow an autosomal recessive 
pattern [2]. However, in 2011 a mutation (c.1790 C > T, p.Ser597Leu) was reported 
to be causative of the disease associated with hypo/oligodontia, that follows an 
autosomal dominant pattern [6].
A syndrome resembling Naxos disease, known as Carvajal syndrome, has been 
described in families from Ecuador and India as well as in Arab-Palestinian families 
[8, 22, 23]. Truncated proteins of desmoplakin, plakoglobin and desmocollin-2 have 
been implemented in the genetic substrate [23]. This syndrome was first described 
by Carvajal-Huerta [22]. Patients present with epidermolytic keratoderma while the 
disease usually manifests at a younger age and the LV is commonly affected [3, 8]. 
Notably, the replacement of the myocytes by fatty tissue is not apparent in Carvajal 
syndrome [24].
4. Pathophysiology and diagnostic criteria
Both plakoglobin (γ-catenin) and desmoplakin, that are linked with Naxos 
disease are associated with myocardial cell adhesion [3, 25]. Plakoglobin has a 
two-fold role in both mechanical contraction and electrical signal conduction; it 
is a component of the desmosomes, interconnecting with the intermediate fila-
ments of desmin, and constitutes a component of the adherens junctions where it 
is connected to the actin skeleton [3, 26]. Similarly, desmoplakin is a cytoplasmic 
protein that links plakoglobin to the intermediate filaments of desmin [3]. The 
defective cell adhesion in the case of the truncated plakoglobin protein, also causes 
a reduction in the connexin-43 levels, a major gap junction protein. The associated 
myocardial gap-junction remodeling, creates a substrate for arrhythmogenic events 
[27]. Furthermore, the defective cell adhesion of the cardiomyocytes leads to their 
apoptosis which is then followed by fibrofatty replacement in the affected ventricles 
[18]. The associated conduction disturbances created can induce arrhythmogenic 
events and sustain re-entry circuits [3].
In the landmark paper Protonotarios et al., all patients were reported to have 
signs of intra-ventricular conduction delay ECG as well as echocardiographic find-
ings of right- or bi-ventricular dysfunction. In more detail, the ECG abnormalities 
that were reported include a wide QRS ≥120 ms and abnormal T-wave inversions 
in seven out of nine patients [5]. The most common abnormalities documented 
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Category Criteria





• Regional RV akinesia, dyskinesia, or aneurysm
• and 1 of the following (measured in end diastole):
 ○ PLAX RVOT ≥32 mm (corrected for body size PLAX/BSA ≥19 mm/m2)
 ○ PSAX RVOT ≥36 mm (corrected for body size PSAX/BSA ≥21 mm/m2)
 ○ or fractional area change ≤33%
By CMR:
• Regional RV akinesia, dyskinesia or dyssynchronous RV
contraction
• and 1 of the following:
 ○ Ratio of RV end-diastolic volume to BSA ≥110 mL/m2 (male) or
≥100 mL/m2 (female)
 ○ or RV ejection fraction ≤40%
By RV angiography:
• Regional RV akinesia, dyskinesia or aneurysm
Minor
By 2-D echocardiography:
• Regional RV akinesia or dyskinesia
• and 1 of the following (measured in end diastole):
 ○ PLAX RVOT ≥29 to <32 mm (corrected for body size PLAX/BSA ≥ 16 to 
<19 mm/m2)
 ○ PSAX RVOT 32 to 36 mm (corrected for body size PSAX/BSA ≥18 to 
<21 mm/m2)
 ○ or fractional area change 33–40%
By CMR:
• Regional RV akinesia or dyskinesia or dyssynchronous RV
contraction
• and 1 of the following:
 ○ Ratio of RV end-diastolic volume to BSA ≥100 to <110 mL/m2 (male) 
or ≥ 90 to <100 mL/m2 (female)




Residual myocytes <60% by morphometric analysis (or < 50% if estimated), 
with fibrous replacement of the RV free wall
myocardium in ≥1 sample, with or without fatty replacement of tissue on 
endomyocardial biopsy
Minor
Residual myocytes 60–75% by morphometric analysis  
(or 50–65% if estimated), with fibrous replacement of the RV free wall 
myocardium in ≥1 sample, with or without fatty replacement of




Inverted T waves in right precordial leads (V1, V2, and V3), or beyond in 
individuals >14 years old (in the absence of complete RBBB ≥QRS 120 ms)
Minor
• Inverted T waves in leads V1 and V2 in individuals >14 years old (in the 
absence of complete RBBB) or in V4, V5 or V6
• Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years old in 
the presence of complete RBBB
5
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in Naxos patients are wide QRS and inverted T-waves in V1-V3 or in all precordial 
leads, while epsilon waves may also be present [3]. An incomplete right bundle 
branch block may also be apparent, while the extrasystoles tend to manifest with 
an LBBB morphology [7]. Flattened T-waves appear in the case of biventricular 





Epsilon wave (reproducible low-amplitude signals between end of QRS 
complex to onset of the T wave) in the right precordial leads (V1 to V3)
Minor
• Late potentials by SAECG in ≥1 of 3 parameters in the absence of QRS 
≥110 ms on the standard ECG
• Filtered QRS duration (fQRS) ≥114 ms
• Duration of terminal QRS <40 μV (low-amplitude signal duration) ≥38 ms
• Root-mean-square voltage of terminal 40 ms ≤20 μV
• Terminal activation duration of QRS ≥55 ms measured from the nadir of 
the S wave to the end of the QRS, including R’, in V1, V2, or
V3, in the absence of complete RBBB
Arrhythmias Major
Nonsustained or sustained ventricular tachycardia of LBBB morphology with 
superior axis (negative or indeterminate QRS in leads II, III, and aVF and 
positive in lead aVL)
Minor
• Nonsustained or sustained ventricular tachycardia of RV outflow configu-
ration, LBBB morphology with inferior axis (positive QRS in
leads II, III, and aVF and negative in lead aVL) or of unknown axis
• >500 ventricular extrasystoles per 24 hours (Holter monitoring)
Family history Major
• ARVC confirmed in a first-degree relative who meets current Task Force 
criteria
• ARVC confirmed pathologically at autopsy or surgery in a first degree 
relative
• Identification of a pathogenic mutation categorized as associated or prob-
ably associated with ARVC in the patient under evaluation
Minor
• History of ARVC in a first-degree relative in whom it is not possible or 
practical to determine whether the family member meets current
Task Force criteria
• Premature sudden death (<35 years of age) due to suspected ARVC in a 
first-degree relative
• ARVC confirmed pathologically or by current Task Force Criteria in a 
second-degree relative
Required for definite diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from different categories; 
borderline: 1 major and 1 minor or 3 minor criteria from different categories
Possible diagnosis: 1 major or 2 minor criteria from different categories.
ARVC, arrhythmogenic right ventricular cardiomyopathy; BSA, body surface area; CMR, cardiac magnetic 
resonance imaging; LBBB, left bundle branch block; PLAX, parasternal long-axis view; PSAX, parasternal short-
axis view; RBBB, right bundle branch block; RV, right ventricular; RVOT, RV outflow tract; SAEG, signal averaged 
ECG.
Adapted from Marcus et al. [31].
Table 1. 
Revised task force criteria for arrhythmogenic right ventricular cardiomyopathy.
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other forms of cardiomyopathies [28]. In echocardiography, dysfunction, hypo-
kinesia and aneurysms are prominent [3, 7]. In histological specimens fibrofatty 
patterns are prominent, while focal myocarditis has also been reported in follow-up 
histology specimens [4]. Both the subepicardial and the mediomural myocardium 
of the involved ventricles is replaced by fibrofatty tissue, while healthy myocytes are 
surrounded by fatty tissue [3, 29]. In immunohistochemical specimens the signal of 
plakoglobin and connexin-43 in the intracellular junctions is diminished [24, 27].
Since the disease belongs in the ARVC spectrum and there are currently no 
specific diagnostic criteria for the cardiac manifestations of Naxos disease, the 
diagnostic criteria of ARVC are widely used [30, 31]. However, while the specific-
ity of the revised task force criteria is high, sensitivity has been shown to be as 
low as 13–20% [32]. Since then, progress has been made regarding tissue charac-
terization through cardiac magnetic resonance (CMR), possibly providing a tool 
of higher diagnostic accuracy, high specificity and high sensitivity [32, 33]. The 
revised task force criteria for ARVC are depicted in Table 1. In November 2020 
the Padua criteria for the diagnosis of ACM was published. The Padua diagnostic 
criteria introduce tissue characterization by contrast enhanced cardiac magnetic 
resonance for detection of fibro-fatty myocardial replacement of both ventricles. It 
also adds new ECG criteria, including depolarization/ repolarization abnormalities 
and ventricular arrhythmias, specific for the LV involvement [34]. The proposed 




Naxos disease is predominantly a condition affecting the right ventricle, 
causing right ventricular failure. Unlike for LV failure, less is known regarding the 
optimal pharmacological therapy. However, the expert consensus regarding the 
management of ACMs suggests that when treating left or right ventricular dys-
function, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers, beta-blockers, mineralocorticoid receptor antagonists, and diuretics, in 
the case of fluid overload, should be considered [35]. Despite the lack of Naxos-
specific guidelines, ACE inhibitors, betablockers, and diuretics are reasonable 
prescribing choices [2]. Dapagliflozine and empagliflozine have been introduced 
in the treatment of heart failure, even in non-diabetic patients [36, 37], while 
sacubitril/valsartan is indicated for patients with left ventricular ejection fraction 
(EF) ≤35% [38]. Anticoagulation treatment is indicated in the case of atrial  
fibrillation/flutter, in the event of intra-cardiac thrombi and can also be consid-
ered in patients with ventricular aneurysms, either left or right [35, 39]. In the 
case of advanced heart failure, patients may benefit from devices such as cardiac 
resynchronization therapy (CRT), often combined with an implantable cardio-
verter-defibrillator (ICD), left ventricular assist devices (LVAD) and assist devices 
for the right ventricle (RVAD or BiVAD) in the setting of an LVAD implantation 
and considered as bridge to transplant [38].
5.2 Arrhythmias and sudden cardiac death
The prognosis of the disease is adverse, especially in the young and annual SCD 
mortality is 2.3% [7, 8]. As risk factors for SCD, the following have been identified: 
history of syncope, onset of symptoms before the age of 35, structural progression 
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before the age of 35, and left-ventricular involvement [7]. However, risk stratifi-
cation of SCD constitutes a challenge. ARVC guidelines and position papers on 
ICD implantation, guide the same decisions in the management of Naxos disease 
[35, 40]. Criteria for risk stratification for SCD is presented in Table 2. A clear 
indication for an ICD implantation is aborted SCD and VT with haemodynamic 
instability, while in the case of VT without haemodynamic compromise it should 
also be considered [35, 40]. An ICD protects from SCD in ARVC either in second-
ary prevention or is justified as primary prevention based on careful judgment of 
risk factors [40–42]. However, the clinical presentation should play a major part in 
the decision making; unexplained syncope, risk markers associated with medical 
history, family history and severity of clinical presentation and deterioration should 
be considered [40]. An ICD is indicated for ACM patients with low ejection fraction 
≤35% and New York Heart Association (NYHA) class II or III, provided that the 
patient’s estimated survival exceeds one year [35]. The same guidelines apply for 
Naxos patients. The first implantation of an ICD in a Naxos patient was reported in 
2000 [43]. Naxos-specific guidelines are rare. Among those, an ICD is indicated for 
patients who are symptomatic or present structural progression especially before the 
age of 35 [8, 44]. Naxos patients, like ARVC patients, should abstain from competi-
tive sports as myocardial stress can exacerbate the dysplasia [40]. Regarding drug 
therapy, beta-blockers (Class I), and possibly amiodarone (Class IIb) and sotalol 
(Class IIb) in special cases have been suggested for patients with ACMs for the con-
trol of arrhythmias and the reduction of ICD shocks [35, 45]. Specifically for Naxos 
patients with recurrent sustained VTs, anti-arrhythmic drugs should be prescribed 
as per the general guidelines of arrhythmias, while amiodarone or sotalol alone or in 
combination with beta-blockers have been suggested [8, 40, 45]. As far as catheter 
ablation is concerned, it should be considered in ACM cases with amiodarone-
refractory recurrent monomorphic VT, recurrent symptomatic drug-refractory 
Estimated Risk Parameters
High risk (>10% / year) Major arrhythmic events
• Cardiac arrest due to ventricular arrhythmia
• Sustained ventricular tachycardia
Intermediate risk (1–10% / 
year)
Major risk factors
• Non-sustained ventricular tachycardia
• Unexplained syncope
• Severe right or left ventricular dysfunction
Minor risk factors
• Male sex, proband
• Frequent ectopic beats (≥1000 premature ventricular beats per day)
• Extent of negative T-waves (beyond V3)
• Inducibility on electrophysiological study
• Extent of right ventricular fibrofatty scarring
• Multiple associated desmosomal mutations
Low risk (<1% / year) No events/no risk factor
• Healthy gene carriers
• Patients with definite ARVC
Adapted from Corrado et al. [46].
Table 2. 
Risk stratification for sudden cardiac death in ARVC.
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sustained VT, symptomatic nonsustained VT or a high ectopic burden (≥1000 pre-
mature ventricular contractions/day) refractory to beta-blockers [35]. Beta-blockers 
are also recommended for patients without an ICD (Class IIa) [35].
5.3 Bioengineering
On the front of cellular and molecular engineering, advances have been made 
that may create a substrate with therapeutic potentials in the future. The pharma-
ceutical substance SB216763 (SB21) (an inhibitor of the glycogen synthase kinase 
GSK-3β) prevented heart failure and reduced mortality when administered early 
on to zebrafish models with induced plakoglobin mutations that resulted in Naxos 
disease. The effect could possibly be attributed to the prevention of the formation 
of an arrhythmic substrate on the intercalated disk level [47]. Further data on 
mammalian models are, however, needed [2, 48].
On the front of induced pluripotent stem cells (iPSCs) that enable the in-vitro 
study of human genetic disorders like ARVC through the induction of mutant 
cardiomyocytes, albeit a challenging field, promising results have been reported 
[49–51]. Researchers have been able to re-create the ARVC phenotype using adult-
like metabolic energetics, proving that adultlike metabolism plays a crucial role 
in establishing ARVC models through iPSCs [49]. Furthermore, cultured ARVC 
cardiomyocytes manifest with adipogenic phenotype and reduced cell surface 
localization of desmosomal proteins, characteristic features of ARVC [50]. Also 
Naxos-ARVC has been created in mice models through a homozygous mutation of 
the plakoglobin gene [52] and of the desmoplakin gene, the latter causing human-
like cardiac arrhythmias, palmoplantar keratosis, and alopecia [53]. Interestingly, 
cardiac function was restored in mice through the normalization of Naxos plako-
globin levels, indicating that it is the downregulation of the protein that causes the 
cardiac dysfunction, rather than the mutation itself [54]. This conclusion, if further 
supported, could have clinical applications in Naxos disease [2]. The article suggests 
that an approach to this would be to use antisense technology to specifically block 
nonsense-mediated decay of mutant plakoglobin mRNA, enabling the expression of 
the truncated protein at increased levels [54, 55].
6. Conclusion
In this chapter key aspects of Naxos disease are presented. Due to its rarity, 
the condition follows the general guidelines for arrhythmias and heart failure, as 
disease-specific criteria is lacking. However, due to its uniqueness, larger Naxos 
registries are needed, as they would illuminate the individual characteristics of 
the disease as well as guide the way to designated guidelines for the management 
of Naxos patients. Possibly, the thorough study of the origins of the disease, the 
genetic substrate and pathogenesis, can offer insights with therapeutic potential.
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